Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 2Lung Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Hematologic Neoplasms 1Glioma 1Genomic Instability 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

tucatinib 1pembrolizumab 1niraparib 1atezolizumab 1Trastuzumab 1Tissue Banks 1GSK-3326595 1Fulvestrant 1Etoposide 1Diet 1Cyclophosphamide 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Ado-Trastuzumab Emtansine × Thoracic × Clear all
NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
131 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡